Gladstone Institutional Advisory LLC Cuts Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Gladstone Institutional Advisory LLC decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,885 shares of the biotechnology company's stock after selling 9,415 shares during the period. Gladstone Institutional Advisory LLC owned 0.08% of Sarepta Therapeutics worth $8,984,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its position in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank raised its position in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after buying an additional 175 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics during the 4th quarter worth $36,000. Finally, UMB Bank n.a. raised its position in Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after buying an additional 197 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Trading Down 1.4 %

Shares of Sarepta Therapeutics stock traded down $1.51 during mid-day trading on Friday, hitting $107.95. 630,697 shares of the stock were exchanged, compared to its average volume of 847,020. Sarepta Therapeutics, Inc. has a twelve month low of $102.15 and a twelve month high of $173.25. The stock has a market capitalization of $10.31 billion, a price-to-earnings ratio of 86.36 and a beta of 0.75. The company has a 50-day simple moving average of $119.42 and a 200 day simple moving average of $124.85. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SRPT shares. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. HC Wainwright restated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. StockNews.com downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday. They set a "hold" rating and a $136.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.